Evidence map›Paper›PMID 37486342›Full record

ArticleACS synthetic biology2023

Multiplexed Guide RNA Expression Leads to Increased Mutation Frequency in Targeted Window Using a CRISPR-Guided Error-Prone DNA Polymerase in

Michael Gossing, Angelo Limeta, Christos Skrekas, Mark Wigglesworth, Andrew Davis, Verena Siewers, Florian David

Open access · hybridAbstract readLetter
In one paragraph

Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Michael GossingDiscovery Sciences, Biopharmaceuticals R&D, AstraZeneca, SE-41320 Gothenburg, Sweden.ORCID 0000-0001-6794-0900
Angelo LimetaDepartment of Life Sciences, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.
Christos SkrekasDepartment of Life Sciences, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.ORCID 0000-0003-2510-495X
Mark WigglesworthDiscovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Alderley Park SK10 2NA, U.K.
Andrew DavisDiscovery Sciences, Biopharmaceutical R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Verena SiewersDepartment of Life Sciences, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.
Florian DavidDepartment of Life Sciences, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.
Novo Nordisk Foundation · DKAstraZeneca (Australia) · AUAstraZeneca (Sweden) · SEAstraZeneca (United Kingdom) · GBChalmers University of Technology · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology, with its ability to target a specific DNA locus using guide RNAs (gRNAs), is particularly suited for targeted mutagenesis. The targeted diversification of nucleotides in

Indexed as

Mutation RateSaccharomyces cerevisiaeCRISPR-Cas SystemsDNADNA-Directed DNA PolymeraseMutationRNADNADNA-Directed DNA PolymeraseRNACRISPRdirected evolutionin vivo mutagenesismultiplexingtargeted mutagenesisyeast

Identifiers

PMID37486342
PMCPMC10443033
OpenAlexW4385186431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.